Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease

Current Gastroenterology Reports

Volumn 5, Issue 6, 2003, Pages 501-505

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CHIMERIC ANTIBODY; CORTICOSTEROID DERIVATIVE; ETANERCEPT; HYDROCORTISONE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G4; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; ONERCEPT; PROTEIN P75; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOGLOBULIN G; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ASPERGILLOSIS; AUTOIMMUNITY; CHIMERA; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DEMYELINATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; HEART FAILURE; HISTOPLASMOSIS; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFUSION SITE REACTION; LISTERIOSIS; LUPUS VULGARIS; LYMPHOMA; MAINTENANCE DRUG DOSE; MILIARY TUBERCULOSIS; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; REMISSION; REVIEW; SEPSIS; TUBERCULOSIS; DRUG ANTAGONISM; IMMUNOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN G; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1542369183     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-003-0040-8     Document Type: Review

References (37)

1. Lugering A, Schmidt M, Lugering N, et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-57.
2. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-11.
3. van den Brande JMH, Braat H, van den Brink GR, et al.: Infliximab but not etanercept induces apopotosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
4. Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
6. Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
7. Sands B, Van Deventer S, Bernstein C, et al.: Long-term treament of fistulizing Crohn's disease: response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology 2002, 122:A81.
8. Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
9. Stack WA, Mann SD, Roy AJ, et al.: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997, 349:521-524.
10. Sandborn WJ, Feagan BG, Hanauer SB, et al.: An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001, 120:1330-1338.
11. Sandborn W, Feagan B, Radford-Smith G, et al.: Randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-a, in patients with moderate to severe Crohn's disease [abstract]. Gastroenterology 2003, 124:A-61.
12. Feagan BG, Sandborn WJ, Baker J, et al.: A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease [abstract]. Gastroenterology 2000, 118:A655.
13. Celltech announces results from CDP 571 studies in Crohn's disease. http://www.inpharma.com/news.
14. Schreiber S, Rutgeerts P, Fedorak R, et al., and the CDP870 Crohn's Disease Study Group: CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD) [abstract]. Gastroenterology 2003, 124:A-61.
15. Rutgeerts P, Lemmens L, Van Assche G, et al.: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003, 17:185-92.
16. Mayer L, Han C, Bala M, et al.: Three dose induction regimen of infliximab (Remicade) is superior to a single dose in patients with Crohn's disease. Am J Gastroenterol 2001, 96:S303.
17. Vermeire S, Noman M, Van Assche G, et al.: Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003, 125:32-39.
18. Cheifetz A, Smedley M, Martin S, et al.: The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenerol 2003, 98:1315-1324.
19. Hanauer S, Rutgeerts P, Targan S, et al.: Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment [abstract]. Gastroenterology 1999, 116:A731.
20. Mohan N, Edwards ET, Cupps TR, et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
21. Brown SL, Greene MH, Gershon SK, et al.: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002, 46:3151-3158.
22. Kwon HJ, Cote TR, Cuffe MS, et al.: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003, 138:807-811.
23. Remicade (infliximab) for IV injection [package insert]. Malvern, PA: Centocor; 2002.
24. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999, 13(Suppl 4):16-22.
25. Schaible TF: Long term safety of infliximab. Can J Gastroenterol 2000, 14(Suppl C):29C-32C.
26. Sandborn WJ, Hanauer SB: Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002, 97:2962-2972.
27. Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
28. Lee JH, Slifman NR, Gershon SK, et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002, 46:2565-2570.
29. Maini RN, Breedveld FC, Kalden JR, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
30. LoBuglio AF, Wheeler RH, Trang J, et al.: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989, 86:4220-4224.
31. Rutgeerts P, D'Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
32. Remicade (infliximab) for IV injection [prescribing information]. Malvern, PA: Centocor; 2002.
33. Sandborn WJ: Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology 2003, 124:1140-1145.
34. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
35. Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124:917-924.
36. Hanauer S, Present D, Targan SR, et al.: CDP571, a humanized monoclonal antibody to TNF-a, is well tolerated in Crohn's disease patients with previous hypersensitivity to infliximab [abstract]. Gastroenterology 2003, 124:A-517.
37. Winter T, Wright J, Ghosh S, et al.: Intravenous CDP870, a humanized anti-TNF antibody fragment, in patients with active Crohn's disease: an exploratory study [abstract]. Gastroenterology 2003, 124:A-377.